Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction
about
A20 is an early responding negative regulator of Toll-like receptor 5 signalling in intestinal epithelial cells during inflammationA20 (TNFAIP3) alleviates CVB3-induced myocarditis via inhibiting NF-κB signalingCurcumin prevents and reverses murine cardiac hypertrophyTargeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signalingSIRT1 mediates the protective function of Nkx2.5 during stress in cardiomyocytes.Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signallingCa2+ influx via TRPC channels induces NF-kappaB-dependent A20 expression to prevent thrombin-induced apoptosis in endothelial cells.Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overloadTumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signalingβ-arrestin2 in infiltrated macrophages inhibits excessive inflammation after myocardial infarctionUbiquitin carboxyl terminal hydrolyase L1-suppressed autophagic degradation of p21WAF1/Cip1 as a novel feedback mechanism in the control of cardiac fibroblast proliferationSignal regulatory protein-α protects against cardiac hypertrophy via the disruption of toll-like receptor 4 signalingInflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway.In vivo delivery of nucleic acids via glycopolymer vehicles affords therapeutic infarct size reduction in vivoCellular repressor of E1A-stimulated genes attenuates cardiac hypertrophy and fibrosis.Inhibition of XO or NOX attenuates diethylstilbestrol-induced endothelial nitric oxide deficiency without affecting its effects on LNCaP cell invasion and apoptosis.Disruption of mindin exacerbates cardiac hypertrophy and fibrosis.Ca2+/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heartTransient receptor potential vanilloid gene deletion exacerbates inflammation and atypical cardiac remodeling after myocardial infarction.Upregulation of neuronal zinc finger protein A20 expression is required for electroacupuncture to attenuate the cerebral inflammatory injury mediated by the nuclear factor-kB signaling pathway in cerebral ischemia/reperfusion ratsIRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling.Sequence variation in PPP1R13L results in a novel form of cardio-cutaneous syndrome.The transcription factor DREAM represses the deubiquitinase A20 and mediates inflammation.Vinexin-β protects against cardiac hypertrophy by blocking the Akt-dependent signalling pathway.The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.Post-infarct sleep disruption and its relation to cardiac remodeling in a rat model of myocardial infarction.Regulatory role of CARD3 in left ventricular remodelling and dysfunction after myocardial infarction.ALK7 protects against pathological cardiac hypertrophy in mice.Increased mortality and aggravation of heart failure in liver X receptor-α knockout mice after myocardial infarction.Cardioprotective role of growth/differentiation factor 1 in post-infarction left ventricular remodelling and dysfunction.Vinexin-β exacerbates cardiac dysfunction post-myocardial infarction via mediating apoptotic and inflammatory responses.Disruption of tumor necrosis factor receptor associated factor 5 exacerbates pressure overload cardiac hypertrophy and fibrosis.The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis.Recombinant frizzled1 protein attenuated cardiac hypertrophy after myocardial infarction via the canonical Wnt signaling pathway.Anti-inflammatory and anti-osteoclastogenic effects of zinc finger protein A20 overexpression in human periodontal ligament cells.MCP-1-induced protein attenuates post-infarct cardiac remodeling and dysfunction through mitigating NF-κB activation and suppressing inflammation-associated microRNA expression.Dickkopf-3 protects against cardiac dysfunction and ventricular remodelling following myocardial infarction.Overexpression of a dominant-negative mutant of SIRT1 in mouse heart causes cardiomyocyte apoptosis and early-onset heart failure.Dickkopf-3 attenuates pressure overload-induced cardiac remodelling.Comparative antiapoptotic effects of KB-R7943 and ischemic postconditioning during myocardial ischemia reperfusion.
P2860
Q24317005-9DFB43C6-9380-4FA3-B8F6-3D8C4C7AD160Q27316099-D3E714B3-3AEE-4964-81DC-B13B5752DC77Q28570267-E519FB9C-DC99-4183-8BAE-AEEE06203E66Q28573220-08A122D0-721E-4A40-ACFA-5F51CDFFA4B4Q33288803-794A90C7-490D-4D8E-B2E9-2899F70851C9Q33690802-E1AA5C67-9100-43A1-A5D8-E591C2495BA0Q33727637-55282203-AB86-4C0E-B535-8C05C7DF73A4Q34068533-70A0227B-858C-426F-A2B8-8556F8D9FFDAQ34615889-28699B17-6FE3-4812-8496-47C10F993D1BQ34827316-FABFE064-0396-404F-B695-5270097030A4Q35147643-6F7174B5-2DDD-4AA2-8E51-DE362780519BQ35576675-AF2D4693-C9B8-4758-9487-933EFE5590ABQ35691449-8BE35E9A-78DA-44EC-B8B7-947051249E4AQ35802123-76664AA8-8E15-481A-94A4-474E9BC1B9FDQ35832100-BF32536C-3ED2-402F-8DEF-4FDF5C31DC09Q36911120-9B0D3602-ADF1-43E1-96DD-D10BF0B7515CQ37073982-3A1E3177-7923-4805-B8AA-534BB2FB9655Q37143342-31270E49-8C36-43BE-8387-85D2BFB65A55Q37160076-B5A7AC92-7DCE-41CA-9381-4D60EBE97830Q37307976-575F5D71-EF8E-4067-AAFD-91EEE5026B0EQ37594217-A18E9A52-63DC-4CD3-9A60-8E5CF1752617Q37672722-C4D697FC-5D6A-4D8D-BFCD-CE12DE9BAD06Q37733779-A0C6AD75-5E8D-4C3E-8E6D-11703D586652Q38317549-F7CEAD83-6D80-4D01-A44E-A390B26F7A0FQ38875774-349C37D9-74CB-4516-8E8F-25AD00654069Q38982144-DAE7A764-F569-4C53-8F25-B3DB70AC2E66Q40435871-EE5C23E1-B424-40AD-82C2-8965A8B11E18Q40651629-2035F422-7721-4774-9EB0-A28B11D6EAC7Q40986115-56D70A5B-ABD1-4944-A235-43E83D62F04DQ41333298-FD035B61-F1AB-444A-93F7-7AE3C0FD85EAQ41469937-6AD0BA24-2300-4D0D-823C-E330DC634909Q42269363-9E4887EE-7649-4610-83ED-E01E4E7EBDF7Q47308542-DC36CA80-CC72-49B7-BFE8-AADA130FB0C2Q48505268-D531CDA6-EC93-4D15-BE6F-1A3476DAFBCFQ53810154-ED85D420-7C22-4861-9DAA-22FBF9444DD8Q54168046-6491032B-A446-45BB-B480-F57973D1F5B5Q54168051-EBB03D0F-4105-43EB-97C9-9EDC2DBFEA85Q54195456-B10799DC-4DE5-43FB-94F3-55E69C52D3EBQ54385043-5B10CE08-666E-4BB0-BFC0-71E54AB62354Q54503699-24546AA3-40B5-4C5A-8654-BB81207A900C
P2860
Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Targeted cardiac overexpressio ...... hy after myocardial infarction
@ast
Targeted cardiac overexpressio ...... hy after myocardial infarction
@en
Targeted cardiac overexpressio ...... hy after myocardial infarction
@en-gb
Targeted cardiac overexpressio ...... hy after myocardial infarction
@nl
type
label
Targeted cardiac overexpressio ...... hy after myocardial infarction
@ast
Targeted cardiac overexpressio ...... hy after myocardial infarction
@en
Targeted cardiac overexpressio ...... hy after myocardial infarction
@en-gb
Targeted cardiac overexpressio ...... hy after myocardial infarction
@nl
prefLabel
Targeted cardiac overexpressio ...... hy after myocardial infarction
@ast
Targeted cardiac overexpressio ...... hy after myocardial infarction
@en
Targeted cardiac overexpressio ...... hy after myocardial infarction
@en-gb
Targeted cardiac overexpressio ...... hy after myocardial infarction
@nl
P2093
P921
P3181
P1433
P1476
Targeted cardiac overexpressio ...... hy after myocardial infarction
@en
P2093
Ai-Bing Wang
Chih-Chuan Liang
De-Pei Liu
Hong-Liang Li
Li-Hong Sun
Ming-Lei Zhuo
Peter P Liu
Qinglin Yang
P304
P3181
P356
10.1161/CIRCULATIONAHA.106.656835
P407
P577
2007-04-10T00:00:00Z